SAN DIEGO, Jan. 6 Orexigen(R) Therapeutics, Inc.(Nasdaq: OREX), a biopharmaceutical company focused on the treatment ofobesity, today announced that the Company will be speaking at the 27th AnnualJ.P. Morgan Healthcare Conference. The details are as follows:
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on thetreatment of obesity. The Company's lead combination product candidates areContrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is inthe later stages of Phase 2 clinical development. Each product candidate isdesigned to act on a specific group of neurons in the central nervous systemwith the goal of achieving appetite suppression and sustained weight loss.Further information about the company can be found at http://www.orexigen.com.Date: Monday, January 12, 2009 Time: 8:00 a.m. - 8:30 a.m. Pacific Location: Westin St. Francis, San Francisco, California Webcast link:
SOURCE Orexigen Therapeutics, Inc.